Estrogen and progesterone receptors in tumors of the human ovary

Hähnel, R.; Kelsall, G. R. H.; Martin, John D.; Masters, Anne M.; McCartney, Anthony J.; Twaddle, Ella

doi:10.1016/0090-8258(82)90021-x

Cited by 36 publications

(13 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Hence ER/PR expression was more among postmenopausal patients as compared to premenopausal patients. Similar results were found in studies conducted by Sylvia et al, Hahnel et al and Agarwal et al [18][19][20] As per staging, ER was expressed as 66.66% in stage III, 66.66% in stage II, 50% in stage I. PR was expressed as 100 % in stage III, 100% in stage II and 25% in stage I. Hogdall E V et al reported that ER positivity in ovarian cancers increases with increasing FIGO stage. [21] Agarwal et al reported that receptor positivity increases with stage of tumour.…”

Section: Section: Pathology Discussionsupporting

confidence: 76%

Ovarian Neoplasms: Histopathological Patterns and Estrogen and Progesterone Receptor Expression in Epithelial Ovarian Tumors

Kaur¹,

Kundal²,

Singh³

et al. 2017

Ann. Int. Med. Den.Res.

View full text Add to dashboard Cite

Background: Both the Estrogen and Progesterone hormones and their receptors are thought to be involved in the process of tumor genesis in ovarian cancer. The main aim of present study was to evaluate the histopathological pattern of ovarian neoplasms and to study the expression of estrogen and progesterone status in ovarian epithelial tumours. Methods: The study was carried out on 60 cases of ovarian neoplasms. Out of all 60 cases, 46 epithelial ovarian neoplasms were studied for estrogen and progesterone expression detected through IHC and their correlation with histopathological pattern, age, menopausal status and stage of tumour was studied. Results: Among the 60 cases, 68.3% were benign, 26.7% were malignant and 5 % were borderline. Surface epithelial tumors constituted 76.66%, Germ cell tumours constituted 15.55% and sex cord stromal tumours constituted 6.66% of all tumours. Serous cystadenoma comprised of 43.33% of all cases. Serous cystadenocarcinoma and mature teratoma both constituted 13.33% of all tumours. ER and PR expression was seen in 34.28% and 31.42% of serous neoplasms respectively. Mucinous neoplasms showed 11.11% positivity for PR expression. Among serous tumours, ER and PR both showed positivity in 75% of malignant tumours and positivity of 19.2% and 19.23% for benign tumours respectively. ER and PR showed higher expression in serous tumours. ER and PR expression was more among postmenopausal females. (66.66% and 75% respectively). Both ER and PR showed higher expression in Stage III ovarian neoplasms.(66.66% and 100% respectively). Conclusion: Surface epithelial tumours were most common histopathological pattern among benign and malignant tumours. Estrogen and Progesterone showed higher expression in serous tumours and in postmenopausal patients. ER and PR expression was more in higher stage of ovarian tumours. So estimation of Estrogen and Progesterone receptors may help to select the women with ovarian malignancy for hormonal therapy.

show abstract

Section: Section: Pathology Discussionsupporting

confidence: 76%

Ovarian Neoplasms: Histopathological Patterns and Estrogen and Progesterone Receptor Expression in Epithelial Ovarian Tumors

Kaur¹,

Kundal²,

Singh³

et al. 2017

Ann. Int. Med. Den.Res.

View full text Add to dashboard Cite

show abstract

“…The presence of ER alone in ovarian malignancies was significantly higher than those measured in normal ovaries or in benign ovarian tumor tissues [2]. Similar results were also described by other investigators demonstrating a high rate of ER measurements in malignant ovarian tissues [3][4][5][6][7].…”

Section: Introductionsupporting

confidence: 78%

“…Despite this, several reports have documented the status of ovarian ER and PR expression as measured in normal ovarian tissue as well as in benign or malignant ovarian tissues of pre-and postmenopausal women [2][3][4][5][6][7]. Willcocks et al [2] measured ER expression in normal ovaries, benign ovarian tumors and in ovarian carcinomas, yielding a concentration of 22, 20 and 57% respectively.…”

Section: Introductionmentioning

confidence: 99%

Estrogen and Progesterone Receptors in Benign Ovarian Tumors of Menopausal Breast Cancer Patients Treated with Tamoxifen

Cohen

Bernheim²,

Fishman³

et al. 1998

Gynecol Obstet Invest

View full text Add to dashboard Cite

In order to assess possible ovarian cell potential for interaction with tamoxifen, thus demonstrating possible effects of this agent on the development of ovarian pathologies through growth stimulation and cell proliferation, we measured estrogen receptors (ER) and progesterone receptors (PR) by immunohistochemical method in 16 benign ovarian tumors removed from 11 postmenopausal breast cancer patients treated with tamoxifen (study group). The results were compared with those measured in 7 similar ovarian tumors obtained from 5 similar patients without tamoxifen treatment (control group I), and in 9 similar tumors removed from 9 age-matched postmenopausal women (control group II). There were no significant differences with regard to ER or PR expression between the study group and control group I and II (ER = 18.75, 0.0 and 11%, respectively; PR = 43.75, 28.5 and 44%, respectively; p = NS). There were also no significant statistical differences between the three groups when subdividing the ovarian pathologies according to different histological types. From the results obtained in this study, it seems that tamoxifen probably does not have any direct influence on the ovaries of menopausal breast cancer patients.

show abstract

“…Steroid receptors have been also identified in several other carcinomas [6,8], in acute and chronic leukemia [9,10], and in non-Hodgkin lymphomas [ 111, but only with breast cancer is receptor content widely used to guide therapy.…”

Section: Introductionmentioning

confidence: 99%

Determination of glucocorticoid receptors in leukemic myeloblasts by isoelectric focusing in polyacrylamide gel

et al. 1985

View full text Add to dashboard Cite

We investigated the optimal conditions for measuring glucocorticoid receptor in blast cells from patients with acute nonlymphocytic leukemia. Cytosol receptor measured with isoelectric focusing was saturated after 60 min of incubation at 0 degrees C with 100 nM of either dexamethasone or triamcinolone. Saturation was achieved when cytosol from at least 7 X 10(6) cells was used for incubation. Trypsin treatment of the cytosol resulted in a sharpened peak of receptor focusing at pH 5.6 with no loss of receptor-bound radioactivity. The two physical forms of glucocorticoid receptor were isolated with DEAE cellulose chromatography. They were both found to focus at pH 5.6 during isoelectric focusing.

show abstract

Estrogen and progesterone receptors in tumors of the human ovary

Cited by 36 publications

References 10 publications

Ovarian Neoplasms: Histopathological Patterns and Estrogen and Progesterone Receptor Expression in Epithelial Ovarian Tumors

Ovarian Neoplasms: Histopathological Patterns and Estrogen and Progesterone Receptor Expression in Epithelial Ovarian Tumors

Estrogen and Progesterone Receptors in Benign Ovarian Tumors of Menopausal Breast Cancer Patients Treated with Tamoxifen

Determination of glucocorticoid receptors in leukemic myeloblasts by isoelectric focusing in polyacrylamide gel

Contact Info

Product

Resources

About